Forge Therapeutics and Evotec Form Strategic ‘Superbug’ Alliance – Combination of leading innovative chemistry efforts with cutting edge anti-infective drug discovery platform –

San Diego, Calif., December 9, 2016 – Forge Therapeutics, Inc. today announced a strategic alliance with Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ...

Forge Therapeutics and Evotec Form Strategic ‘Superbug’ Alliance – Combination of leading innovative chemistry efforts with cutting edge anti-infective drug discovery platform –2017-10-10T16:05:19-07:00

Forge Therapeutics Adds Superbug Experts Drs Brad Spellberg and Andrew Tomaras to Leading Antibiotic Advisory Team

San Diego, Calif., September 12, 2016 – Forge Therapeutics, Inc. announced the additions of Dr. Brad Spellberg, M.D., Chief Medical Officer of Los ...

Forge Therapeutics Adds Superbug Experts Drs Brad Spellberg and Andrew Tomaras to Leading Antibiotic Advisory Team2017-10-09T22:06:55-07:00

Forge Therapeutics Presenting ‘Superbug’ Program at World Anti-Microbial Resistance Congress and Harvard Anti-Infectives Rx Conference

San Diego, Calif., September 7, 2016 – Forge Therapeutics, Inc., announced presentations on its lead program targeting LpxC with novel chemistry to combat ...

Forge Therapeutics Presenting ‘Superbug’ Program at World Anti-Microbial Resistance Congress and Harvard Anti-Infectives Rx Conference2017-10-09T17:21:04-07:00

Forge Therapeutics Scientific Co-Founder Awarded National Chemistry Honor

San Diego, Calif., August 16, 2016 – Forge Therapeutics, Inc. announced today Dr. Seth Cohen, Ph.D., co-founder of Forge Therapeutics and Professor in ...

Forge Therapeutics Scientific Co-Founder Awarded National Chemistry Honor2017-10-09T17:28:00-07:00

Forge Therapeutics Receives 1st Federal Funding Award to Advance Superbug Program

World-renowned antibiotic experts form Key Opinion Team to advise Forge San Diego, Calif., July 26, 2016 – Forge Therapeutics, Inc. today announced its 1st ...

Forge Therapeutics Receives 1st Federal Funding Award to Advance Superbug Program2017-10-10T16:10:47-07:00

Forge Therapeutics Announces ‘Superbug’ Data at ASM Microbe 2016

First ever non-hydroxamate inhibitor of LpxC to demonstrate efficacy in preclinical models of Gram-negative bacteria infection San Diego, Calif., June 14, 2016 – Forge ...

Forge Therapeutics Announces ‘Superbug’ Data at ASM Microbe 20162017-10-09T17:31:16-07:00
© Copyright 2020 -  Forge Therapeutics.   |   All Rights Reserved
TwitterLinkedIn
Go to Top